<DOC>
	<DOCNO>NCT00542412</DOCNO>
	<brief_summary>Evaluate efficacy riluzole 50-mg bid define compare percentage riluzole-treated subject experience death , permanently assist ventilation ( PAV ) tracheostomy , group recent historical control treatment amyotrophic lateral sclerosis ( ALS ) .</brief_summary>
	<brief_title>CARE Canadian ALS Riluzole Evaluation</brief_title>
	<detailed_description />
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Riluzole</mesh_term>
	<criteria>Diagnosis ALS confirm follow definition : ( ) '' Probable '' `` Definite '' Amyotrophic Lateral Sclerosis ( ALS ) accord El Escorial criterion ( b ) '' Peripheral '' onset form ( limb involvement ) `` Bulbar '' form ALS duration five year , base inquiry early symptom disease A subject simultaneously present bulbar peripheral sign onset ALS disease stratify bulbar onset group . The neurologic progression subject match bulbar onset ALS subject . Pulmonary Function : force vital capacity ( FVC ) must 3 60 % study entry . Females childbearing potential must document use acceptable birth control method IUD oral contraceptive . Previous treatment riluzole Tracheostomy , expect undergo tracheostomy within two month study inclusion Signs clinical dementia and/or major psychiatric disorder Serious concomitant disease handicap likely interfere subject 's assessment impact subject 's survival A multiple conduction block show nerve conduction study electromyogram The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2007</verification_date>
</DOC>